^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Bria-IMT (SV-BR-1-GM) (Immunostimulant, G-CSF stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
Published date:
04/13/2022
Excerpt:
BriaCell Therapeutics Corp...announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer (breast cancer that has spread beyond the breast)....Initial data on patient survival in this study was...over 12 months (average of 9 prior regimens) compared with 7-10 months in a study in 3 rd line breast cancer patients (those who failed 2 prior regimens for metastatic breast cancer).
